Lexeo Therapeutics (LXEO) Common Equity (2022 - 2026)

Lexeo Therapeutics has reported Common Equity for 5 years, with the latest figure at $231.5 million in Q1 2026.

• Quarterly Common Equity rose 162.72% year-over-year to $231.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $231.5 million (up 162.72% YoY) and the FY2025 annual result came in at $246.7 million, up 111.11% from the prior year.
• Common Equity slipped to $231.5 million in Q1 2026 per LXEO's latest filing, from $246.7 million in the prior quarter.
• Over five years, Common Equity peaked at $246.7 million in Q4 2025 and troughed at -$162.8 million in Q3 2023.
• A 5-year average of $59.6 million and a median of $116.8 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2024: Common Equity sank 64.49% in 2023, then surged 239.46% in 2024.
• Over 5 years, Common Equity stood at -$113.0 million in 2022, then surged by 200.51% to $113.5 million in 2023, then increased by 2.91% to $116.8 million in 2024, then soared by 111.11% to $246.7 million in 2025, then slipped by 6.15% to $231.5 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $231.5 million, $246.7 million, and $120.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.